Full text is available at the source.
Abstract
Emerging evidence suggests that glucagon-like peptide-1 receptor agonists (GLP-1RAs) may aid in weight loss for individuals with inflammatory bowel disease (IBD).
- GLP-1RAs are commonly used therapies for type 2 diabetes and obesity.
- Retrospective observational studies indicate potential benefits of GLP-1RAs in IBD populations.
- Findings regarding IBD-related outcomes and adverse events are based on real-world evidence.
- Current evidence lacks randomized controlled trials specifically evaluating GLP-1RA for IBD treatment.
- Safety considerations and the need for prospective trials are highlighted as priorities.
Simplified